Author:
Kohler Sven,Salsali Afshin,Hantel Stefan,Kaspers Stefan,Woerle Hans J.,Kim Gabriel,Broedl Uli C.
Subject
Pharmacology (medical),Pharmacology
Reference44 articles.
1. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012
2. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences;Gallo;Diab Vasc Dis Res,2015
3. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Haering;Diabetes Care,2013
4. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial;Roden;Lancet Diabetes Endocrinol,2013
5. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Haering;Diabetes Care,2014
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献